PhRMA Chief Medical Officer and Executive Vice President William Chin
Dr. William W. Chin is the Chief Medical Officer and Executive Vice President at PhRMA beginning in July 2013 where he leads PhRMA’s continuing efforts in science advocacy in the drug discovery and development ecosystem.
He was the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS). In this role, Dr. Chin spearheaded efforts to design and implement the vision for research at HMS, with special emphasis on interdisciplinary and translational research that crosses departmental and institutional boundaries.
Chin is a Harvard-trained endocrinologist and longstanding faculty member. His impressive career is exemplified in part by his extensive bibliography of nearly 300 papers, chapters and books, most of which were generated during his 25 years on the Harvard Medical School faculty. During his tenure as a faculty member in the Department of Medicine at Brigham and Women’s Hospital, he became chief of the Genetics Division and a Howard Hughes Medical Institute investigator, advancing to professor of Medicine, and Obstetrics, Gynecology and Reproductive Biology at HMS.
As a pioneering molecular endocrinologist at HMS, Dr. Chin embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. His investigations often demonstrated a translational research theme, connecting basic laboratory discoveries to their physiologic relevance in animal models and humans. He has been honored with numerous awards for research, mentorship and leadership.
Prior to HMS, Dr. Chin was at Eli Lilly and Company, where he had worked for the last decade, most recently as senior vice president for Discovery Research and Clinical Investigation. He received his AB (Chemistry; summa cum laude) from Columbia University and his MD from Harvard Medical School.
- PhRMA's Outlook on Personalized Medicines. Remarks at the 9th Annual Personalized Medicine Conference
- Biopharmaceutical Sector Leads the Way in Clinical Trial Data Sharing
- PhRMA Joins Accelerating Medicines Partnership to Advance Discovery and Development of New Treatment
- Understanding the science behind drug discovery
- Responsible Clinical Trial Data Sharing Will Expand Scientific Knowledge and Improve Public Health
- Harvard personalized medicine conference
Related news stories / opinion pieces
Page last updated 02/03/14 ~ 1:55 pm EST